Home > Drugs A – Z > Tiotropium (By breathing)

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Tiotropium is used to treat chronic obstructive pulmonary disease (COPD). COPD is a lung disease that also includes chronic bronchitis (swelling of the tubes leading to the lungs) and emphysema (damage to the air sacs in the lungs). It is also used as maintenance treatment for asthma in adults and children 6 years of age and older. Tiotropium belongs to the family of medicines known as… Read more
Brand names include
Spiriva, Spiriva Respimat, Spiriva Respimat Institutional Pack 28ACT
Drug classes About this
Bronchodilator
Combinations including this drug

What works? Research summarized

Evidence reviews

Tiotropium bromide for COPD: Executive summary of final report A05-18, Version 1.0

The aims of this report were ■ to assess the benefit of tiotropium bromide compared to placebo or other pharmacological treatment options, alone or in combination, and ■ the comparative benefit assessment of the two forms of application of tiotropium bromide, namely the HandiHaler and the Respimat, in each case for the long-term inhalation treatment of patients with COPD with respect to patient-relevant outcomes.

Tiotropium versus ipratropium bromide in the management of COPD

Chronic obstructive pulmonary disease (COPD) is a lung disease that includes the conditions chronic bronchitis and emphysema. COPD is mainly caused by smoking or inhaling dust, which leads to blockage or narrowing of the airways. The symptoms include breathlessness and a chronic cough. Tiotropium is an inhaled medication, taken once a day, to help widen the airways (bronchodilator) and is used in the management of COPD. Ipratropium bromide is also a bronchodilator but has a shorter duration of action and has to be taken several times a day.

Tiotropium for stable chronic obstructive pulmonary disease

Tiotropium (Spiriva) is a bronchodilator drug that has been developed to open the airways in the lungs effectively with once daily dosing. The main aims of therapy in COPD are to reduce exacerbations and related hospitalisations, improve quality of life, and reduce the rate of decline in lung function. The evidence from the trials in the review indicates that, compared with a placebo and ipratropium, tiotropium does reduce exacerbations and related hospitalisations and improves quality of life and symptoms in people with moderately severe COPD, although the evidence with regards to decline in lung function is less clear. Tiotropium caused dry mouth. Compared with other commonly used drugs in COPD, such as long‐acting beta agonists (including salmeterol), there is not enough evidence for us to draw reliable conclusions. In order to better understand the effects of this drug we need long‐term studies (over several years), studies conducted in mild and severe COPD, and additional studies that measure outcomes in relation to other agents used in the treatment of this condition.

See all (81)

Summaries for consumers

Tiotropium versus ipratropium bromide in the management of COPD

Chronic obstructive pulmonary disease (COPD) is a lung disease that includes the conditions chronic bronchitis and emphysema. COPD is mainly caused by smoking or inhaling dust, which leads to blockage or narrowing of the airways. The symptoms include breathlessness and a chronic cough. Tiotropium is an inhaled medication, taken once a day, to help widen the airways (bronchodilator) and is used in the management of COPD. Ipratropium bromide is also a bronchodilator but has a shorter duration of action and has to be taken several times a day.

Tiotropium for stable chronic obstructive pulmonary disease

Tiotropium (Spiriva) is a bronchodilator drug that has been developed to open the airways in the lungs effectively with once daily dosing. The main aims of therapy in COPD are to reduce exacerbations and related hospitalisations, improve quality of life, and reduce the rate of decline in lung function. The evidence from the trials in the review indicates that, compared with a placebo and ipratropium, tiotropium does reduce exacerbations and related hospitalisations and improves quality of life and symptoms in people with moderately severe COPD, although the evidence with regards to decline in lung function is less clear. Tiotropium caused dry mouth. Compared with other commonly used drugs in COPD, such as long‐acting beta agonists (including salmeterol), there is not enough evidence for us to draw reliable conclusions. In order to better understand the effects of this drug we need long‐term studies (over several years), studies conducted in mild and severe COPD, and additional studies that measure outcomes in relation to other agents used in the treatment of this condition.

Combined inhalers compared to tiotropium inhalers for the treatment of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is a general term referring to chronic bronchitis and emphysema, or both. COPD occurs when airflow to the lungs is restricted. Symptoms include cough and breathlessness and inhalers are commonly used to prevent and relieve these symptoms. COPD is usually caused by smoking and the best way to improve symptoms is to give up smoking.

See all (27)

PubMed Health Blog...

read all...